Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) provided significant antitumor activity in various tumors, mainly carrying deleterious mutations of BRCA1/BRCA2 genes. Only few data are available regarding the cardiac and vascular safety profile of this drug class. We carried out a...

Descripción completa

Detalles Bibliográficos
Autores principales: Palazzo, A., Ciccarese, C., Iacovelli, R., Cannizzaro, M.C., Stefani, A., Salvatore, L., Bria, E., Tortora, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163166/
https://www.ncbi.nlm.nih.gov/pubmed/36893518
http://dx.doi.org/10.1016/j.esmoop.2023.101154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163166/
https://www.ncbi.nlm.nih.gov/pubmed/36893518
http://dx.doi.org/10.1016/j.esmoop.2023.101154

Ejemplares similares